Fortrea Holdings Inc. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Fortrea Holdings Inc. (FTRE)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Fortrea is a leading global contract research organization (CRO) providing biopharmaceutical product and medical device development solutions. The company operates in a single reporting segment, Clinical Services, offering Phase I through IV clinical trial management, clinical pharmacology, and consulting services. Fortrea was spun off from Labcorp Holdings Inc. on June 30, 2023. In 2024, the company completed the divestiture of its Enabling Services Segment (Patient Access and Endpoint Clinical), which is now reported as discontinued operations.
Key Financial Metrics (2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Revenue (Continuing Ops) | $2,696.4 million | $2,842.5 million |
| Operating Income (Loss) | $(161.9) million | $32.0 million |
| Net Income (Loss) | $(328.5) million | $(25.2) million |
| Diluted EPS (Continuing Ops) | $(3.03) | $(0.36) |
| Operating Cash Flow | $262.8 million | $168.4 million |
| Backlog | $7.7 billion | Not explicitly stated for 2023 in summary |
| Total Debt (Principal) | $1,142.0 million | $1,640.0 million (at Spin) |
| Cash and Equivalents | $118.5 million | $108.6 million |
Margins: Direct costs as a percentage of revenue increased to 80.2% in 2024 from 79.2% in 2023. The effective income tax rate was 1.3% for 2024.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 5.1% year-over-year, driven by a 5.2% decline in organic revenue due to lower pass-through costs, fewer new business wins prior to the Spin, and a slower backlog burn rate. This was partially offset by growth in clinical pharmacology services.
- Operating Loss: The company reported an operating loss of $161.9 million in 2024 compared to an operating income of $32.0 million in 2023. This shift was primarily due to increased Selling, General, and Administrative (SG&A) expenses (up 25.1%) related to standalone operations and restructuring charges ($50.1 million vs. $21.2 million in 2023).
- Discontinued Operations: The sale of the Enabling Services Segment resulted in a loss on disposal of $19.6 million and a net loss from discontinued operations of $57.0 million for the year.
- Debt Reduction: The company paid down $70.2 million on Term Loan A and $412.5 million on Term Loan B during 2024, reducing total principal debt from the initial $1,640.0 million incurred at the Spin.
- Restatements: The company restated prior period financial statements (2022 and 2023) to correct errors related to goodwill impairment, revenue recognition, and expense accruals. These corrections were deemed immaterial to the prior periods individually but significant to the current period's comparability.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted the successful remediation of previously identified material weaknesses in internal controls over financial reporting by the end of 2024. The company continues to invest in technology, data, and AI to drive efficiency. The divestiture of the Enabling Services Segment is expected to allow the company to focus on its core Clinical Services business.
Subsequent Events: On February 28, 2025, Fortrea amended its credit agreement to increase the maximum quarterly Total Leverage Ratio to 6.00:1.00 through mid-2026, providing additional financial flexibility.
Key Risks and Contingencies:
- Backlog Realization: Backlog of $7.7 billion may not fully convert to revenue due to potential customer cancellations, delays, or scope reductions.
- Customer Concentration: The top two customers accounted for 14.3% and 10.5% of 2024 revenue, respectively. The top ten customers represented 53% of revenue.
- Regulatory and Compliance: Risks related to data privacy (GDPR, CCPA), anti-corruption laws (FCPA), and clinical trial regulations (FDA, EMA) remain significant.
- Internal Controls: While material weaknesses were remediated in Q4 2024, the company previously faced challenges with internal controls following the Spin.
- Activist Investor: The company entered into a Cooperation Agreement with Starboard Value LP in February 2025 regarding board composition changes.
Investor Verification Checklist
- Restatement Impact: Verify the specific financial impact of the 2022 and 2023 restatements on current year comparability and future guidance.
- Backlog Quality: Assess the stability of the $7.7 billion backlog, specifically the risk of cancellations or delays in the current macroeconomic environment.
- Debt Covenants: Review the implications of the February 2025 credit agreement amendment and the company's ability to meet the adjusted leverage ratios.
- Discontinued Operations: Confirm the final purchase price adjustments and any remaining transition service obligations related to the sale of the Enabling Services Segment.
- Internal Controls: Monitor the effectiveness of the newly implemented internal controls over financial reporting in the coming quarters.
- Customer Concentration: Evaluate the dependency on the top two customers and the potential impact of their R&D spending decisions.